- Danaher Corporation (NYSE:DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE:CTLT).
- According to the sources, the recent moves by the life science firm valued Catalent at a significant premium.
- It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.
- Related: Danaher Says 2022 'Another Great Year,' Delivers Around 10% Core Revenue Growth.
- Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added.
- "As a matter of company policy, Catalent does not comment on market rumors or speculation," the report cited a company spokesperson.
- Also Read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
- Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE:NVO) obesity drug Wegovy.
- Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and AstraZeneca Plc (NASDAQ:AZN).
- Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more